Amylyx Pharmaceuticals, Inc. (AMLX) Financials

AMLX Assets vs Liabilities

DateAssetsLiabilities
2023-12-31 517.5 million 84.0 million
2023-09-30 466.6 million 48.2 million
2023-06-30 453.6 million 67.2 million
2023-03-31 408.0 million 55.3 million

AMLX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-12-31 13.2 million 9.5 million
2023-09-30 -5.5 million 10.2 million
2023-06-30 8.3 million 10.0 million
2023-03-31 -5.3 million 7.5 million

AMLX Net Income

No data available :(

AMLX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-12-31 371.4 million - 4.2 million
2023-09-30 355.0 million - 4.8 million
2023-06-30 357.3 million - 5.3 million
2023-03-31 345.7 million - 5.8 million

AMLX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-12-31 69.2 million
2023-09-30 69.7 million
2023-06-30 70.1 million
2023-03-31 70.9 million

AMLX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-12-31 356000 44.9 million 52.2 million -
2023-09-30 357000 30.0 million 48.7 million -
2023-06-30 278000 29.0 million 43.4 million -
2023-03-31 250000 24.2 million 44.0 million -

AMLX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-12-31 108.4 million 9.4 million
2023-09-30 102.7 million 5.2 million
2023-06-30 98.2 million 5.6 million
2023-03-31 71.4 million 5.3 million

AMLX

Price: $1.93

52 week price:
1.76
31.77

Earnings Per Share: 0.70 USD

P/E Ratio: 1614

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 390250

Market Capitalization: 182.7 million

Links: